Advances in CAR T-Cell Therapy for the Treatment of Multiple Myeloma

摘要

H&O What is the rationale for the use of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma? NS Multiple myeloma cells express B-cell maturation antigen (BCMA), a protein that is not expressed on many other types of cells. By targeting BCMA with an active T cell, it is possible to achieve a specific cytotoxic effect. H&O Are there other potential target antigens in multiple myeloma? NS There are fewer target antigens in multiple myeloma than might be expected. Two known antigens are CD38 and SLAMF7. CD38 is mainly used for antibody-based therapy. This antigen is a target for daratumumab (Darzalex, Janssen) and isatuximab-irfc (Sarclisa, Sanofi Genzyme). CD38 is present on several other types of cells, so it may not be the best target for CAR T-cell therapy. SLAMF7 is targeted by the antibody elotuzumab (Empliciti, Bristol-Myers Squibb).